{"id":11435,"date":"2022-07-01T20:37:35","date_gmt":"2022-07-02T00:37:35","guid":{"rendered":"https:\/\/www.cancerresearch.org\/event\/the-biotechs-conundrum-in-immuno-oncology-between-a-rock-and-a-hard-place-weighing-hot-versus-cold-tumors-cpi-naive-versus-cpi-experienced-patients\/"},"modified":"2022-07-14T15:04:15","modified_gmt":"2022-07-14T19:04:15","slug":"webinar-biotech-conundrum-in-immuno-oncology","status":"publish","type":"cri_events","link":"https:\/\/www.cancerresearch.org\/es\/events\/webinar-biotech-conundrum-in-immuno-oncology","title":{"rendered":"The Biotech\u2019s Conundrum in Immuno-Oncology: Between a Rock and a Hard Place \u2013 Weighing Hot Versus Cold Tumors, CPI-Na\u00efve Versus CPI-Experienced Patients"},"content":{"rendered":"<p>The advent of the age of immuno-oncology has led to a dramatic shift in our conception of how to treat cancer patients. The approval of six <a href=\"https:\/\/www.cancerresearch.org\/treatment-types\/immunomodulators\">checkpoint inhibitors<\/a>&nbsp;in the United States has transformed clinical management and patient outcomes in some tumor types, but in other indications the clinical benefit has been more modest or even negligible.&nbsp;<\/p>\n<p>With the two leading checkpoint inhibitors (Merck&rsquo;s Keytruda and BMS&rsquo; Opdivo) leading the way here, with some 1,400 combination trials ongoing, a diverse array of approaches, targets, and modalities are being combined with checkpoint inhibitors.<\/p>\n<p>The need to increase patient responsiveness to treatment and extend duration of remissions across all cancers has resulted in an intensive clinical development push around combinations, generating debate about which types of tumors make better targets for these therapies and what point in a patient&rsquo;s course of treatment is the optimal time to administer them.<\/p>\n<p>This webinar, with esteemed colleagues from Merck, MD Anderson, f-star, eFFECTOR, and Cancer Research Institute, is intended to be a lively discussion of the pros and cons, challenges, and opportunities that these various clinical development strategies entail.<\/p>\n<p><strong>Vanessa M. Lucey, PhD, MBA, director of&nbsp;CRI Clinical Accelerator and Venture Fund, discusses the <a href=\"\/scientists\/immuno-oncology-landscape\">immuno-onocology landscape<\/a> in this webinar for the biotechnology industry.&nbsp;<\/strong><\/p>\n<p>This webinar is organized by&nbsp;Cello Health BioConsulting.<\/p>\n<p><a class=\"btn btnAccent2 btnExternal\" href=\"https:\/\/register.gotowebinar.com\/register\/6462304128519695629?utm_source=cancer-research-institute&amp;utm_medium=website&amp;utm_campaign=accelerator\" target=\"_blank\" rel=\"noopener\">Register<\/a><\/p>\n<p><strong>Vanessa M. Lucey, PhD, MBA, director of&nbsp;CRI Clinical Accelerator and Venture Fund, will also speak on a panel at <a href=\"https:\/\/www.cancerprogressbydh.com\/\" target=\"_blank\" rel=\"noopener\">Cancer Progress<\/a> on May 6, 2020, at Convene in New York City. <\/strong>Cancer Progress is organized by&nbsp;Cello Health BioConsulting.<\/p>\n<p><em>Photo by&nbsp;Andras Vas&nbsp;on&nbsp;Unsplash<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CRI&#39;s Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.&nbsp;<\/p>\n","protected":false},"featured_media":586,"template":"","events_categories":[203],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-11435","cri_events","type-cri_events","status-publish","has-post-thumbnail","hentry","events_categories-cri-speaks"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biotech\u2019s Conundrum in Immuno-Oncology<\/title>\n<meta name=\"description\" content=\"CRI&#039;s Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotech\u2019s Conundrum in Immuno-Oncology\" \/>\n<meta property=\"og:description\" content=\"CRI&#039;s Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-14T19:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/66a43f25-e6cd-4123-b0e9-696c2e2093ca.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Biotech\u2019s Conundrum in Immuno-Oncology\" \/>\n<meta name=\"twitter:description\" content=\"CRI&#039;s Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/66a43f25-e6cd-4123-b0e9-696c2e2093ca.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology\",\"url\":\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology\",\"name\":\"Biotech\u2019s Conundrum in Immuno-Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/3f7ee870-0ba9-4938-8af7-1e6fcc9bb95b.jpg\",\"datePublished\":\"2022-07-02T00:37:35+00:00\",\"dateModified\":\"2022-07-14T19:04:15+00:00\",\"description\":\"CRI's Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/3f7ee870-0ba9-4938-8af7-1e6fcc9bb95b.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/3f7ee870-0ba9-4938-8af7-1e6fcc9bb95b.jpg\",\"width\":700,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Event\",\"item\":\"https:\/\/www.cancerresearch.org\/events\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The Biotech\u2019s Conundrum in Immuno-Oncology: Between a Rock and a Hard Place \u2013 Weighing Hot Versus Cold Tumors, CPI-Na\u00efve Versus CPI-Experienced Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biotech\u2019s Conundrum in Immuno-Oncology","description":"CRI's Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology","og_locale":"es_ES","og_type":"article","og_title":"Biotech\u2019s Conundrum in Immuno-Oncology","og_description":"CRI's Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0","og_url":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology","og_site_name":"Cancer Research Institute","article_modified_time":"2022-07-14T19:04:15+00:00","og_image":[{"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/66a43f25-e6cd-4123-b0e9-696c2e2093ca.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_title":"Biotech\u2019s Conundrum in Immuno-Oncology","twitter_description":"CRI's Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0","twitter_image":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/66a43f25-e6cd-4123-b0e9-696c2e2093ca.jpg","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology","url":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology","name":"Biotech\u2019s Conundrum in Immuno-Oncology","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/3f7ee870-0ba9-4938-8af7-1e6fcc9bb95b.jpg","datePublished":"2022-07-02T00:37:35+00:00","dateModified":"2022-07-14T19:04:15+00:00","description":"CRI's Vanessa Lucey, PhD, discusses the immuno-onocology landscape in this webinar for the biotechnology industry.\u00a0","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/3f7ee870-0ba9-4938-8af7-1e6fcc9bb95b.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/3f7ee870-0ba9-4938-8af7-1e6fcc9bb95b.jpg","width":700,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/events\/webinar-biotech-conundrum-in-immuno-oncology#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Event","item":"https:\/\/www.cancerresearch.org\/events"},{"@type":"ListItem","position":3,"name":"The Biotech\u2019s Conundrum in Immuno-Oncology: Between a Rock and a Hard Place \u2013 Weighing Hot Versus Cold Tumors, CPI-Na\u00efve Versus CPI-Experienced Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events\/11435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_events"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/586"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=11435"}],"wp:term":[{"taxonomy":"events_categories","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/events_categories?post=11435"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=11435"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=11435"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=11435"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=11435"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=11435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}